1. Home
  2. VSTM vs AFMD Comparison

VSTM vs AFMD Comparison

Compare VSTM & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSTM
  • AFMD
  • Stock Information
  • Founded
  • VSTM 2010
  • AFMD 2000
  • Country
  • VSTM United States
  • AFMD Germany
  • Employees
  • VSTM N/A
  • AFMD N/A
  • Industry
  • VSTM Biotechnology: Pharmaceutical Preparations
  • AFMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSTM Health Care
  • AFMD Health Care
  • Exchange
  • VSTM Nasdaq
  • AFMD Nasdaq
  • Market Cap
  • VSTM 132.0M
  • AFMD 53.3M
  • IPO Year
  • VSTM 2012
  • AFMD 2014
  • Fundamental
  • Price
  • VSTM $3.88
  • AFMD $3.36
  • Analyst Decision
  • VSTM Strong Buy
  • AFMD Strong Buy
  • Analyst Count
  • VSTM 8
  • AFMD 5
  • Target Price
  • VSTM $14.57
  • AFMD $16.25
  • AVG Volume (30 Days)
  • VSTM 1.1M
  • AFMD 80.0K
  • Earning Date
  • VSTM 11-06-2024
  • AFMD 11-12-2024
  • Dividend Yield
  • VSTM N/A
  • AFMD N/A
  • EPS Growth
  • VSTM N/A
  • AFMD N/A
  • EPS
  • VSTM N/A
  • AFMD N/A
  • Revenue
  • VSTM $10,000,000.00
  • AFMD $7,959,927.00
  • Revenue This Year
  • VSTM N/A
  • AFMD N/A
  • Revenue Next Year
  • VSTM $125.69
  • AFMD $48.98
  • P/E Ratio
  • VSTM N/A
  • AFMD N/A
  • Revenue Growth
  • VSTM N/A
  • AFMD N/A
  • 52 Week Low
  • VSTM $2.10
  • AFMD $2.92
  • 52 Week High
  • VSTM $14.22
  • AFMD $8.95
  • Technical
  • Relative Strength Index (RSI)
  • VSTM 63.77
  • AFMD 44.84
  • Support Level
  • VSTM $3.11
  • AFMD $3.28
  • Resistance Level
  • VSTM $3.76
  • AFMD $3.51
  • Average True Range (ATR)
  • VSTM 0.33
  • AFMD 0.17
  • MACD
  • VSTM 0.04
  • AFMD 0.04
  • Stochastic Oscillator
  • VSTM 94.26
  • AFMD 55.79

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Share on Social Networks: